After inflammation-induced demyelination, such as in the disease multiple
sclerosis, endogenous remyelination often fails. However, in animal models of
demyelination induced with toxins, remyelination can be quite robust. A
significant difference between inflammation-induced and toxin-induced
demyelination is the response of local cells within the lesion, including
astrocytes, oligodendrocytes, microglia/macrophages, and NG2+ cells, which
respond to inflammatory stimuli with increased extracellular matrix (ECM)
protein and chondroitin sulfate proteoglycan (CSPG) production and deposition.
Here, we summarize current knowledge of ECM changes in demyelinating lesions, as
well as oligodendrocyte responses to aberrant ECM proteins and CSPGs after
various types of demyelinating insults. The discovery that CSPGs act through the
receptor protein tyrosine phosphatase sigma (PTPσ) and the Rho-ROCK
pathway to inhibit oligodendrocyte process extension and myelination, but not
oligodendrocyte differentiation (Pendleton et
al., Experimental Neurology (2013) vol. 247, pp. 113-121), highlights
the need to better understand the ECM changes that accompany demyelination and
their influence on oligodendrocytes and effective remyelination.